(Q37945270)

25 August 2017

title

Drugs in development for chronic hepatitis C: a promising future (English)

1 reference

25 August 2017

1 reference

1 reference

1 reference

Paul J Pockros

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

13 October 2011

1 reference

Expert Opinion on Biological Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

1611-1622

1 reference

The global burden of hepatitis C

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Virology of hepatitis B and C viruses and antiviral targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

21 January 2018

Cyclophilin inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

A perspective on modelling hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.627851

10.1517/14712598.2011.627851

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference